"One of those 'not to be missed' conferences on our annual calendar." - Philip Thorpe, Ph.D., Professor, University of Texas Southwestern Medical Center

"The conference provides a nice balance between what's currently in the clinic and exciting new entities emerging. The two conferences sit nicely with each other and provide opportunity to move between the two." - Anthony Shock, Ph.D., Director, Immunology Project Management, UCB, United Kingdom

"This is the most informative antibody conference giving new insight on emerging trends in the therapeutic antibody landscape." - Jean-Luc Teillaud, Ph.D., Research Director, Antibody BioEngineering Lab, INSERM, France

"This 21st meeting was a great jump into the 21st century. Antibody engineering is still a growing area, and lots of good science and tremendous clinical achievements were presented. The poster sessions gave the opportunity to better meet the scientists. Once again, a great meeting." - Thierry Wurch, Ph.D., Head, Molecular & Cellular Biology, Institut de recherches Pierre FABRE, France

"It was a great conference. The amount of innovation in the field was astounding to find, and the variety of topics was a very good mix - there was always something new every day." - Faisal Malik, Research Associate, Agensys, Inc.

"The perfect combination between top academic groups and the leading industrial players makes this conference the ideal opportunity to share and discuss the latest developments in antibody technology." - Frédéric Mourlane, Ph.D., Scientist, Covagen AG, Switzerland

"The conference was a perfect mix of academic and industry participants and the topics covered ranged from new research results to interesting clinical results." - Sarah Batey, Ph.D., Research Scientist, Covagen AG, Switzerland

"The depth of information and examples presented in the Biosimilar session was superior to any biosimilar conference I attended in recent months." - Adriana E. Manzi, Ph.D., Managing Director, Atheln, Inc.

"Good conference with 2 parallel sessions so that there is always something of interest ongoing." - Christian Klein, Ph.D., Head, Oncology Programs, Roche Glycart AG, Switzerland

"Always a great conference to get a general update on progress in the antibody field." - John Desjarlais, Ph.D., Vice President, Research, Xencor, Inc.

"Overall the breadth covered was very nice. There was also a nice balance between industry and academia." - Kevin Schutz, Ph.D., Postdoctoral Fellow, Adimab

"This was a wonderful conference full of high-level presentations and big names in the field, with great coverage in the antibody field. I came away with the impression that just about anything that you could think of being done with antibodies is being done. Also, it was exciting to get to hear what companies are doing and the challenges they face with developing products/drugs." - Joseph Piccirilli, Ph.D., Associate Professor, The University of Chicago

"The conference gave me a unique prospective about the field of antibody engineering, and included important and timely discussions with key experts in the field." - Mahmoud Zubaidi, Ph.D., Research Scientist, EMD Millipore